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rhe valvular disease highlights at the Scientific Session of
he 2004 American College of Cardiology (ACC) national
eeting were focused on newer therapies for mitral regur-
itation (MR), a glimpse at the ongoing interest in percu-
aneous approaches to valve replacement, the improvement
n outcomes of valvular surgery patients with poor left
entricular (LV) function, an update of our knowledge base
or endocarditis, and a novel observation regarding func-
ional tricuspid regurgitation (TR) in patients with pulmo-
ary hypertension and a dilated LV.
Skeletal myoblast implantation into an area of myocardial
nfarction initially was thought to improve diastolic function
ore than systolic function (1). More recent studies have
uggested regional systolic LV function may improve as well
2), and the concept has now been extended to human trials
3). Whether myoblast transplantation might not only
mprove regional ventricular function but also reduce abnor-
al mitral leaflet tethering and the severity of ischemic MR
as addressed in a sheep model by Messas et al. (4) from
aris, France, and Boston. After inducing MR by creating
n acute infero-basal myocardial infarction, three-
imensional echocardiography was used to visualize the LV
hamber dimensions and mitral valve anatomy. Two
onths after recovery, the animals were randomized, with
ne-half receiving autologous skeletal myoblast implanta-
ions in multiple sites within the infarcted area. The animals
ere then re-imaged two months after the implantations.
nimals that received myoblast implantation had less pro-
ression in their MR, less increase in their LV end-systolic
olume, and less measurable tethering distance from the
nterior annulus to the tip of the ischemic papillary muscle.
n addition, the myoblast animals had a better overall
jection fraction (EF) and better wall motion scores on the
ollow-up study. These data raise the possibility of improv-
ng ischemic MR by use of such myoblast transplantation
echniques.
Another novel approach to the problem of MR has been
ecent attempts at percutaneous mitral repair using catheter-
ased techniques. In general, these methods have involved
he use of a crimping-type catheter placed in the coronary
inus to reduce the mitral annular size (5) or the creation of
double-orifice mitral valve by the transseptal delivery of a
lip device that grasps the mitral leaflet edges (6). This latter
ethod has undergone previous surgical trials with and
ithout an accompanying surgical annuloplasty (7). Dr.
eldman presented the current status of the phase 1 U.S.
rials on the edge-to-edge percutaneous technique. Of note,
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Alinic College of Medicine, Rochester, Minnesota.lthough there have been previous publications demonstrat-
ng that the surgical edge-to-edge mitral repair method does
ot induce a significant mitral gradient (8), Sportouch et al.
9) reported at these meetings that some resting and exercise
itral gradients can be demonstrated, and a moderate
mount of cardiogenic exercise limitation was observed in
ne-third of patients. Percutaneous methods for reducing
R hold the potential for providing enormous benefit for
atients with MR, especially those associated with cardio-
yopathy, who might otherwise not be surgical candidates.
The interest in percutaneous approaches to aortic valve
eplacement also remains high, with several devices being
nvestigated and reported in either the in vitro setting or in
arly animal studies. At the ACC meetings, the French
roup, led by Dr. Cribier, also provided a further update on
he current status of the initial six patients in whom this
ype of device was implanted. All of the patients were not
onsidered surgical candidates. Because of the large size of
he sheath and device catheter (24-F sheath), the transseptal
pproach has been used to avoid placing such a device into
he arterial system. They reported one procedural death and
oted one week after the procedure that the aortic valve area
ad increased from 0.57 to 1.67 cm2, with an increase in the
eft ventricular ejection fraction (LVEF) from 24% to 39%
n the five survivors (10). The era of percutaneous valve
eplacement seems under way, but still a long way from
idespread clinical application.
From the surgical standpoint, Bhudia et al. (11) reported
retrospective series on the Cleveland Clinic’s experience in
perating on patients with severe aortic insufficiency (AI)
nd poor LV function (LVEF 30%). They separated their
xperience with this group (n 88) into two time segments:
972 to 1984 and 1985 to 1999. Hospital mortality before
985 was as high as 50% in 1972, and progressively fell
uring the next 12 years. After 1985, they claim no
perative deaths occurred (0 of 35). Rather remarkably, as
ell, they found no difference in the long-term (up to 10
ears) survival curve between patients operated on after
985, as compared with a matched cohort of patients with
I and an LVEF 30%. These data suggest that there may
e no level of measurable LV dysfunction below which
ortic valve surgery for AI should be withheld.
There also continues to be interest in the use of combined
r “hybrid” procedures combining percutaneous coronary
ntervention (PCI) with subsequent valvular surgery. The
roup at the Brigham and Women’s Hospital reported their
xperience from 1997 to 2003 with 26 such patients (12).
ll were hemodynamically unstable and considered high-
isk valve/coronary artery bypass grafting (CABG) patients.
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f five days after PCI. Concomitant CABG was performed
n 10 patients. Operative mortality was low (1 [3.8%] of 26),
lthough five-year survival was 44%. It was not clear how
any received ticlopidine or clopidogrel after the coronary
tent procedure, and whether this would have blunted the
nthusiasm for this approach. The data are provocative in
uggesting that such hybrid procedures are at least feasible
nd apparently safe.
The puzzle as to why calcium deposits in heart valves over
ime was further investigated in a variety of abstracts. Kaden
t al. (13), from Germany, for instance, extracted normal,
clerotic, and stenotic tricuspid aortic valves and, using a
emi-quantitative immunostaining method, looked for the
resence of C-reactive protein (CRP) within the valves.
hey found it absent in normal valves, present in sclerotic
alves, and strongly present in stenotic valves. When cul-
ured aortic valve myofibroblasts were then stimulated with
RP, they noted an increased expression of matrix
etalloproteinase-1 (MMP-1). Others have reported an
ncrease in MMP-1 in aortic stenosis (14). Matrix metal-
oproteins are proteolytic enzymes that lead to the degrada-
ion of the extracellular matrix; overexpression has been
ssociated with a variety of processes, most notably osteo-
rthritis (15).
The relationship between rheumatic valve calcification
nd inflammation was investigated by the groups at the
ayo Clinic and Northwestern University (16). Extracted
heumatic heart valves were compared to normal human
alves. The valves were studied by a variety of methods,
ncluding micro-computed tomography, hematoxylin-eosin
taining, and Masson’s trichrome staining for anatomic
eatures. Immunohistochemistry was used to localize os-
eopontin protein, alpha-actin, and CD34. Stains were also
ade for vascular endothelial growth factor (VEGF), von
illebrand factor, and human macrophages (CD68). The
ottom-line finding from the studies was that calcification
as observed in mineralized tissue, with VEGF and CD34
ppearing in areas of inflammation. New vessel formation
as only found in the rheumatic valvular tissue. Inflamma-
ory markers were much more evident in the rheumatic
alves and were minimally present in normal valves. The
uthors’ conclusions suggest a possible mechanism for the
ngoing rheumatic process in these affected valves. These
bservations appear to confirm that angiogenesis and ongo-
ng osteoblastic bone formation are active and ongoing
rocesses in rheumatic heart valve tissue.
The first results from the newly organized prospective
nternational Endocarditis Database were also presented by
abell et al. (17). Thirty-four centers in 15 countries
articipated, and 1,024 cases from January 2000 to Novem-
er 15, 2002 were available for review. Some of the initial
bservations include the fact that preceding dental proce-
ures are now less common (7.9%) than other invasive
rocedures (18.7%). Of interest, Staphylococcus aureus
32.4%) now leads all other organisms as the cause ofndocarditis, including infection from Streptococcus viridans
13.1%) and Enterococcus faecalis (10.6%). Surgery is required
or 45.2% during the acute episode. Complications are
requent, with embolic events (stroke 16.7%, other emboli
2.7%), heart failure (31.3%), and intracardiac abscess
16.2%) leading the way. Even in an era of enhanced
iagnostic tools and antibiotics, death still occurred in a
isappointingly high percentage (19.4%). The univariate
redictors of a fatal outcome include age, diabetes, hemo-
ialysis, long-term indwelling catheters, stroke, congestive
eart failure, and an intracardiac abscess. The most deadly
rganisms include coagulase-negative staphylococci (26%),
taphylococcus aureus (24.2%), and enterococci (21.1%). This
ata base provides a sobering look at endocarditis in the
odern era. It will be an invaluable resource for making
mprovements in our diagnosis and treatment regimens of
his devastating disorder.
Finally, an interesting echocardiographic and homody-
amic feature was presented by Vaturi et al. (18). In patients
ith pulmonary hypertension, the authors observed a
reater degree of TR when LV dysfunction was present.
hen the tricuspid apparatus was examined in greater
etail, they observed bulging of the interventricular septum
oward the right ventricle in patients with LV dysfunction,
esulting in displacement of the tricuspid chordae and
bnormal tricuspid leaflet tethering. The abnormal tether-
ng allowed for superior buckling of the anterior leaflet and
estriction of the septal leaflet. This consequence was the
roduction of an eccentric tricuspid jet and more TR. In
act, an eccentric TR jet was impressively more evident in
he LV dysfunction patients compared with those with
ormal LV function (68% vs. 7%, p  0.001).
eprint requests and correspondence: Dr. Bijoy Khandheria,
ayo Medical School, 200 First Street SW, Rochester, Minnesota
5905-0001. E-mail: khandheria@mayo.edu.
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